Canopy Cancer Collective brings together medical care providers, interdisciplinary teams, cancer researchers, and philanthropic and industry partners in an effort to develop and scale best practices and innovations applicable to the fight against pancreatic cancer. No content on this site is to be considered to be a recommendation or medical advice.
Resources
-
Download the free white paper:
https://canopycancer.org//epi-pertwhitepaperAuthors: Rebekkah Schear, MIA; Rebecca Muñoz, EdD, MPH; Dallas Lawry, DNP, FNP-C, AOCNP; Shelby Yaceczko, DCN, RDN-AP, CNSC, CCTD; Mary-Eve Brown, RD, LDN, CSO; Whitney B. Christie, MS, RD, CSO, CNSC, FAND; Ashley Cox, MS, RDN, CSO; Amy Hacker-Prietz, PA-C; Shelli Hardy, MCN, RD, CSO, LD; Bailey Irvin, RD, CSO, LD; Megan Kitagawa, MS, RD, CNSC; Kaitland R. Lauterbach, MS, RD, CSO, LD/N; Cassadie Moravek, BS; Allison Rosenzweig, PhD
Purpose: This white paper was conceptualized by the Canopy Cancer Collective Learning Health Network (Canopy) and Polaris Global Health Solutions (Polaris) in alignment with Canopy’s mission to scale best practices and bold innovation that transform patient care and outcomes in pancreatic cancer. In 2023, Canopy network members set a network-wide goal to screen every patient seen across their 14 NCI-designated cancer centers for exocrine pancreatic insufficiency (EPI). In doing so, they uncovered a critical gap: there was no standardized screening process or tool, and many centers lacked the capacity and infrastructure to screen for EPI routinely or prioritize its management. To achieve the network-wide goal—and effectively identify and treat enzyme deficiencies revealed through screening—best-practice recommendations were urgently needed. To support development of such recommendations, funding was sought, ultimately leading to the development of this paper. Polaris led the project, which included conducting qualitative research, convening the Expert Working Group on Exocrine Pancreatic Insufficiency (EPI) and Pancreatic Exocrine Replacement Treatment (PERT) in Pancreatic Oncology, and developing the framework for the white paper. Canopy provided clinical and administrative oversight and access to data, experts, historical knowledge, and resources. Members of the Expert Working Group contributed their extensive clinical expertise to the overall direction of the white paper, shaping the statements and writing specific sections.
Study period: February 2024 – July 2025
Contact: For permission requests, please contact Canopy Cancer Collective at support@canopycancer.org.
Strategic partners:
-
-
Under no circumstances does Canopy provide any medical advice and it is not licensed to do so. By accessing and using this site, you acknowledge that there is no professional relationship, including but not limited to a doctor-patient relationship, between you and Canopy or any of its employees, professionals, partners, agents, creators, or authors (collectively “Affiliates”), and neither Canopy nor any of its Affiliates shall have any liability whatsoever in that regard. Canopy and its Affiliates specifically disclaim any and all liability for personal injury, property damage, or other damages of any kind, whether special, indirect, consequential, or compensatory, that may result directly or indirectly from the use of, or reliance on, any publication or content on this site.
No part of any publication or content on this site may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of Canopy, except in the case of brief quotations for non-commercial, educational, or critical review purposes, as permitted by copyright law. For permission requests, please contact Canopy Cancer Collective at support@canopycancer.org. Canopy provides publications and content as a service to its members and community, which are for informational purposes only.